Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). HMG-CoA reductase inhibitors: a review of published clinical trials and pharmacoeconomic evaluations.
D000328:Adult; D008076:Cholesterol, HDL / Q000187:drug effects; D008078:Cholesterol, LDL / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D008875:Middle Aged; D013673:Technology Assessment, Biomedical
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors